Tier 4 — mechanistic

Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen

Antonios D. Tsiailanis, Constantinos C. Tellis, Paraskevi Papakyriakopoulou, Androniki D. Kostagianni, Vasileios Gkalpinos, Christos M. Chatzigiannis, Nikolaos Kostomitsopoulos, Georgia Valsami, Alexandros D. Tselepis, Andreas G. Tzakos
Molecules 2023 28(5):2311

Bibliography

PubMed
PMID 36903557
PubMed Central
PMC10005222
DOI
10.3390/molecules28052311

Study snapshot

DesignPreclinical formulation and pharmacology study
ModelIn silico targets, platelet aggregation assays and C57BL/6J mouse pharmacokinetics
Sample
Intervention4′-DHA-apigenin hybrid and olive-oil formulation compared with parent apigenin and DHA
Duration
EndpointsADP-induced platelet aggregation; TRAP-6-induced aggregation; Arachidonic-acid-induced aggregation; Plasma stability; Mouse pharmacokinetics

What the study showed, in plain terms

This study engineered a DHA-apigenin hybrid to improve antiplatelet activity and oral exposure.

Key findings

The hybrid inhibited multiple platelet-activation pathways more strongly than its parent compounds in vitro, and an olive-oil formulation increased measured apigenin bioavailability by 262% in mice.

What this study can and cannot tell us

The tested molecule is a synthetic hybrid, not standard apigenin. The work does not justify replacing prescribed antiplatelet or anticoagulant therapy with supplements.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology